TRV130

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Pain

Conditions

Pain

Trial Timeline

Oct 20, 2015 → Oct 23, 2015

NCT ID

NCT02520297

About TRV130

TRV130 is a phase 2 stage product being developed by Trevena for Pain. The current trial status is terminated. This product is registered under clinical trial identifier NCT02520297. Target conditions include Pain.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02656875	Phase 3	Completed	Dec 1, 2015	Aug 1, 2017	Acute Pain
NCT02520297	Phase 2	Terminated	Oct 20, 2015	Oct 23, 2015	Pain

Competing Products

20 competing products in Pain

See all competitors

Product	Company	Stage	Hype Score
PRF110- oily solution (Ropivacaine)	PainReform	Phase 2	44
PRF110	PainReform	Phase 2	44
PRF-108 + Placebo + Ropivacaine + PRF-110	PainReform	Phase 1/2	33
TRV130 1.5 mg + TRV130 3 mg + TRV130 4.5 mg + Morphine 10 mg + Placebo	Trevena	Phase 1	25
Oliceridine + Placebo + Morphine	Trevena	Phase 3	69
Oliceridine + Placebo + Morphine	Trevena	Phase 3	69
TRV130	Trevena	Phase 3	69
TRV130 + Morphine + Placebo	Trevena	Phase 2	44
LY3556050 + Placebo	Eli Lilly	Phase 2	52
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine	Pacira Biosciences	Approved	80
Nanoformed Piroxicam IR Tablet + Felden (piroxicam) Tablets + Brexidol (piroxicam) Tablets	Nanoform Finland	Phase 1	28
0.75% bupivacaine + .75% bupivacaine + .75% bupivacaine	SI-BONE	Approved	77
LY3526318 + Placebo	Eli Lilly	Phase 2	52
LY3857210 + Placebo	Eli Lilly	Phase 2	52
OK-101 0.05% + OK-101 0.1% + Placebo	OKYO Pharma	Phase 2	44
YHD1119 + Lyrica	Yuhan	Phase 1	33
YHD1119 + Lyrica	Yuhan	Phase 1	33
YHD1119 + Lyrica	Yuhan	Phase 3	77
YHD1119 300mg + YHD1119 300mg	Yuhan	Phase 1	33
pregabalin sustained release tablet + pregabalin immediate release capsule	Yuhan	Approved	85

Other Products from Trevena

TRV130Phase 3

Oliceridine + Placebo + MorphinePhase 3

TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboPhase 2

TRV130 + Morphine + PlaceboPhase 2